BRAF and Marinesco-Sjogren syndrome: Moreover, based on the fact that combining BRAF and EGFR inhibition could induce a transient MSI-H phenotype [32], Morris et al. presented fascinating results of a phase I/II trial including pre-treated patients with MSS and BRAF V600E mCRC who received the combination of encorafenib, cetuximab, and nivolumab [33].